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quarterly per-prescription reimbursements were deﬁned as total reimbursement 
amounts divided by total prescriptions. The market shares were calculated based on 
the proportion of total prescription numbers. RESULTS: The total reimbursement for 
AMDs increased from $1.6 million in 1991 to $156 million in 2004, and dropped to 
$115 million in 2008. Prescriptions for AMDs increased from 56,410 in 1991 to 
948,597 in 2004, and then dropped to 542,093 in 2008. The ergot prescriptions 
increased from 25,540 in 1991 to 47,543 in 1995, then gradually decreased to 6,367 
in 2008. A similar utilization trend was found for ergot combination products. Mean-
while, triptan prescriptions increased from 23,523 in 1995 to 912,978 in 2004, and 
dropped to 524,922 in 2008. The market share for triptans increased dramatically 
from 0% in 1994 to 97% in 2008, while the market share for ergot derivatives and 
ergot combination products decreased from 45% and 55% in 1991 to 1% and 2% 
in 2008, respectively. The per-prescription cost of branded triptans has steadily 
increased since 1994, regardless of newer brand entries. CONCLUSIONS: Triptan use 
has increased dramatically and dominated the AMD market. However, triptan utiliza-
tion dropped 34.91% in 2006. This may be due to the implementation of Medicare 
Part D.
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ANTIEPILEPTIC DRUG UTILIZATION AND MEDICAID REIMBUSEMENT 
TRENDS FROM 1991 TO 2008
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OBJECTIVES: Antiepileptic drugs (AEDs) are one of the most frequently prescribed 
medication classes in U.S. The objectives of this study were to describe AED utiliza-
tion, price and reimbursement trends and to analyze the market share competition 
between traditional and newer AEDs. METHODS: A retrospective, descriptive time-
series analysis was performed using the National Medicaid pharmacy claims database 
from 1991 to 2008. Quarterly number of prescriptions and reimbursement data 
were calculated for the trends analysis. Study drugs included all brand and generic 
names of newer AEDs (e.g., gabapentin, lamotrigine, topiramate, fosphenytoin) and 
traditional AEDs (e.g., tiagabine, valproate, zonisamide, carbamzepine). Market share 
for AEDs was quantiﬁed annually. The quarterly price per prescription was calculated 
by dividing the total reimbursement by the total number of prescriptions. RESULTS: 
The total number of newer AED prescriptions increased from 32,837 prescriptions 
totaling $2.2 million reimbursement in 1993 to 7.7 million totaling $1.2 billion in 
2005, and dropped to 4.3 million totaling $847 million in 2008. Meanwhile, tra-
ditional AED prescriptions increased from 5.14 million totaling $154 million reim-
bursement in 1991 to 20.5 million totaling $1.22 billion in 2004, and dropped to 
11.5 million totaling $447 million in 2008. The average annual increase in number 
of prescriptions was 71.3% for newer and 6.95% for traditional AEDs. The market 
share of newer AED prescriptions increased from 1% in 1993 to 28% in 2005, and 
27% in 2008. Fosphenytoin remained the most expensive newer AED with price of 
$211 in 1996 and $391 in 2005. Valproic acid and clorazepate were the most 
expensive traditional AEDs, with prices varying from $150 to $600. CONCLU-
SIONS: There has been substantial increase in use of AED, which may be due to 
off-label use, new indications, and as adjunct therapy. A signiﬁcant drop in AED 
utilization trends since 2004 may potentially be due to Medicare part D introduction 
and patent expiration.
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OBJECTIVES: Multiple sclerosis (MS) is a chronic illness leading to permanent dis-
ability. As the disease progresses, MS patients may require home personal care (HPC). 
HPC assists patients with activities of daily living (ADLs) and homemaking, so patients 
can continue living in their homes. This study examines the extent as well as the bar-
riers and facilitators of HPC use by MS patients. METHODS: We analyzed data for 
1577 participants in the 2000–2005 Sonya Slifka survey of MS patients. This survey 
provides information on disease status, socio-demographics, family information, and 
HPC use. We constructed 3 outcome measures: use of paid HPC, use of help with 
ADLs or instrumental ADLs (IADLs), and unmet need. Logistic regression with sam-
pling weights and robust standard errors were employed to examine the association 
between each outcome and patient characteristics. RESULTS: Greater disability was 
associated with greater use of paid HPC (P < 0.001) and greater assistance received 
for ADLs/ IADLS (P < 0.001). Patients on Medicaid used more paid HPC (OR = 1.74, 
p = 0.01) and had less unmet need (OR = 0.53, p = 0.03). Medicare beneﬁciaries 
received more assistance with ADLs/IADLs (OR = 1.42, p = 0.02), but did not receive 
more paid care. Patients living with a spouse/partner purchased fewer services (OR = 
0.64, p = 0.01), while receiving more help overall with functional limitations or chores 
(OR = 2.06, p < 0.01). Patients with greater family income reported lower unmet need 
(OR = 0.36, p < 0.01). CONCLUSIONS: Type of insurance and marital status are 
important predictors of HPC use among the MS population. While patients who live 
with a spouse/partner often have higher family income and can afford more paid HPC, 
they appear to delegate the more burdensome ADL care to their family, while being 
more inclined to pay for help with homemaking. Overall, these patients had lower 
unmet needs and used less paid help than patients living alone.
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OBJECTIVES: Alzheimer’s disease is the sixth-leading cause of death in the United 
States. The health and economic costs associated with the disease are enormous. 
We forecast and quantify this burden until year 2050 and evaluate the potential 
impacts of delayed onset of Alzheimer’s disease. METHODS: We use a dynamic 
micro-simulation model to predict health status (Alzheimer’s disease as one of the 
measures) and economic situations of Americans 50 years and older, from year 2004 
to 2050. To estimate the burden of Alzheimer’s disease, we estimate a scenario in 
which there is no incidence of Alzheimer’s disease and compare outcomes with 
projections of the status-quo over future years. To evaluate the impacts of potential 
treatments to delay the onset of Alzheimer’s disease, we run three scenarios in which 
there is 2-year, 4-year, or 6-year delay of onset of Alzheimer’s disease. The main 
data sources are the Health and Retirement Study and the Aging, Demographics, 
and Memory Study. The health outcome measured is Quality-Adjusted Life Years. 
Economic outcomes include earnings and tax revenues, health care costs and long-
term care costs (total, Medicare, Medicaid), opportunity costs for unpaid caregivers, 
and Social Security outlays. RESULTS: The population with Alzheimer’s disease will 
increase by more than 150 percent in year 2050. Relative to the status-quo, eliminat-
ing Alzheimer’s disease would raise tax revenues, and reduce cumulative Medicare 
costs. Alternatively, cumulative Medicaid spending and Social Security beneﬁts would 
increase, outweighing the savings in Medicare spending and raised tax revenues. We 
will also present the gains in QALYs and savings in unpaid care-giving under dif-
ferent intervention scenarios. CONCLUSIONS: Preventing Alzheimer’s disease will 
increase life expectancy and quality of life. However, these health beneﬁts will 
increase government spending as increased longevity results in longer outlays of 
annuities and health spending.
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OBJECTIVES: Insomnia is the most common sleep complaint worldwide. Our study 
aims to identify physician and patient characteristics likely to inﬂuence insomnia 
prescription patterns. METHODS: The project utilized data from National Ambula-
tory Medical Care Survey, conducted by the US. Department of Health and Human 
Services. The study subjects were selected from 2006 outpatient visits in which at 
least one frequently used insomnia medication was prescribed. A series of population-
based descriptive analyses were used to estimate the national weighted frequencies 
of selected insomnia drug prescriptions. We further constructed a weighted logistic 
regression model to estimate the odds ratio and marginal probabilities of covariates 
toward predicting insomnia drug prescriptions. RESULTS: Among the 901.8 million 
outpatient visits that took place in the US in 2006, an estimated 21.07 million visits 
included at least one insomnia drug prescription. The results from a multivariate 
logistic regression showed that a patient’s race and age, physician’s clinic ownership, 
type of ofﬁce setting, and employment status were signiﬁcantly associated with 
insomnia drug prescriptions. Black patients were 2.4 times more likely to receive 
insomnia prescription than were white patients (OR = 2.4; 95% Wald CI (1.26–
4.69)). Older patients were more likely received insomnia prescription than were 
younger patients. Patients with 3–5 visits over the course of 12 months received 
fewer insomnia prescription than did patients with only 1 visit (OR = 0.44; 95% 
Wald CI (0.21–0.93)). Physicians who worked in the academic health center pre-
scribed fewer insomnia drugs than did physicians who worked in the private practices 
(OR = 0.29; 95% Wald CI (0.09–0.91)). Employed or contracted physicians pre-
scribed a signiﬁcantly higher number of insomnia drugs than did owner physicians 
(OR = 3.6; 95% Wald CI (1.87–6.78)). CONCLUSIONS: Our ﬁndings indicate 
various sociodemographic disparities in the use of insomnia prescriptions. The study 
also demonstrated a comprehensive analytical framework, which is especially appli-
cable to population-based data mining research.
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OBJECTIVES: To evaluate the agreement between data derived from medical charts 
of patients with multiple sclerosis (MS) and from a health care claims database. 
METHODS: This data source comparison was a secondary objective in a study utiliz-
ing both claims and linked medical chart data. Patients with MS were identiﬁed in a 
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health care claims database and the claims and medical charts for a subset of this 
population were reviewed to extract information pertaining to disease-modifying 
therapy, corticosteroid therapy, MS-related procedures, and diagnosis and relapse 
dates. The agreement between the data sources for each type of information was 
identiﬁed. RESULTS: From a total population of 11,326 MS patients in the claims 
database, 300 had their medical records reviewed. Among patients with claims for 
glatiramer acetate (n = 68), 95.6% also had it indicated in their charts. Claims agreed 
with charts for 91.8% of patients with a claim for intramuscular interferon β-1a (n = 
85), 81.8% of patients with a claim for subcutaneous interferon β-1a (n = 55), and 
87.5% of patients with a claim for interferon β-1b (n = 48). Methylprednisolone was 
the most commonly indicated corticosteroid in both data sources, and among patients 
with evidence of a methylprednisolone ﬁll in the claims (n = 114), 66.7% also had a 
prescription indicated in their chart. Most patients with claims-based evidence of 
MS-related procedures also had them indicated in their charts: 71.0% with MRI, 
81.0% with lumbar puncture, and 66.7% with evoked potential testing. For both 
diagnosis and relapse dates, at least half of the patients had perfect agreement. CON-
CLUSIONS: Claims and medical charts provide complementary information with a 
degree of overlap. Claims appear to approximate chart data with regard to certain 
MS-related variables, such as dates and disease-modifying therapy, but the data 
sources also provide unique information which might be differentially suited to 
addressing diverse research questions.
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OBJECTIVES: Since its development in the 80’s, variations of the Alzheimer’s Disease 
Assessment Scale-Cognitive subscale (ADAS-Cog), a Clinician-Reported Outcome 
(ClinRO) measure, have been used to monitor disease progression and treatment 
efﬁcacy in Alzheimer’s disease. The objective of this study was to identify all versions 
used as a basis for translation in Mapi Institute projects and to take stock of existing 
translations. METHODS: The review was based on all ADAS-Cog translation projects 
performed by Mapi Institute. RESULTS: Sixteen projects were identiﬁed representing 
a total of 70 languages and 219 translations. Translations were based on 11 source 
versions which differed in terms of content (number of items, order of items and 
instructions), and format. The number of items ranged from 11 to 15. Four studies 
used 13 items, but only in two cases the same items were used but in a different order. 
Four studies used 12 items: only two studies used the same items (with a different list 
of words for the Word Recognition Task), but again in a different order. Format and 
instructions differed in all cases. In most projects the source version provided by the 
sponsor was a single document mixing instructions with the rater and response forms. 
Only in 3 cases the original consisted in a separate instruction manual and response 
forms. With regard to available translations, more than one translation was identiﬁed 
in 56 of the 70 available languages and in one language as many as 7 translations. 
CONCLUSIONS: The abundance of different versions of the same questionnaire both 
in its original US English form as in translation makes comparisons between studies 
or pooling of data difﬁcult for both researchers and users. In the light of FDA’s recent 
PRO guidance it would be beneﬁcial to demand the same scientiﬁc rigor when using 
ClinROs in international studies.
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OBJECTIVES: Explore the effect of adjusting for multiple comparisons in analyzing 
outcome variables between more than two strata. METHODS: Health-related quality 
of life (HRQoL) via SF-12 Health Survey was measured at baseline for 191 patients 
in a U.S. multiple sclerosis observational study. HRQoL was summarized in two 
continuous variables: Physical Component Score (PCS-12) and Mental Component 
Score (MCS-12). Patient work status was expressed by one categorical variable with 
four values: Working Full-time (W), Working Part-time (WP), Not Working due to 
MS (NW-MS), Not Working due to other reasons (NW). Generalized linear models 
were used to measure the overall association HRQoL and work status. Pairwise 
comparisons were conducted between the HRQoL means with respect to each of the 
four categories of work status. The Bonferroni method was used to control the fami-
lywise error rate under multiple comparisons test. RESULTS: Overall association 
between Work Status and HRQoL was statistically signiﬁcant (p-values: <.001 for all 
measures), suggesting that HRQoL differs by work status. Pairwise comparisons 
showed that only the NW-MS group was statistically signiﬁcantly different from all 
other groups (all p-values <.001) in PCS-12 and different from W and WP groups in 
MCS-12 (p-value: W = 0.03, WP = < .001), while all other comparisons were not 
signiﬁcantly different from each other. If the Bonferroni adjustment is not applied, the 
pairwise comparisons lead to more differences being signiﬁcant (p-value: W vs WP = 
0.04 in PCS-12 and MCS-12). CONCLUSIONS: Even though the overall association 
between two variables may be statistically signiﬁcant, if the categorical variable has 
more than two categories, then applying multiple comparisons adjustments to all 
pairwise comparisons more appropriately tests the statistical signiﬁcance of the differ-
ences between these individual categories. Neglecting to account for the fact that 
multiple comparisons are being made may lead to erroneous conclusions about dif-
ferences in outcomes.
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OBJECTIVES: To evaluate evidence on effectiveness of intravitreal Avastin for neo-
vascular age related macular degeneration (AMD). METHODS: We searched the 
Medline database for articles on bevacizumab for neo-vascular AMD, published 
between January 1, 2005 and September 1, 2009. The search criteria were English 
language manuscripts, human studies and search terms “bevacizumab”, “Avastin”, 
“age-related macular degeneration”, “ARMD”, “AMD”,”intra-vitreal” as a major 
heading. Boolean operators were used to combine the search terms. Studies in which 
primary outcome measures were visual acuity (VA) and central retinal thickness (CRT) 
were included for review. Two reviewers independently selected studies, assessed 
methodological quality using Scottish Intercollegiate Grading Network (SIGN) system. 
RESULTS: Overall, there were 520 citations, of which only 216 were relevant after 
title and abstract screening. Sixty-seven manuscripts were ﬁnally included for review, 
of which three were systematic reviews, three were randomized Controlled Trials 
(RCT), 49 were pre-post/ non-randomized studies and 13 were studies on safety and 
adverse effect. Three RCTs show bevacizumab to be more effective than PDT (with 
or without triamcinolone). However, these RCTs had several methodological issues; 
evidence from these RCT’s was of moderate quality. Several pre-post and non-ran-
domized studies have also suggested the effectiveness of bevacizumab, but these studies 
had several design limitations and hence the quality of evidence was deemed poor. 
Pooled outcome estimates, showed bevacizumab therapy,on average, improved VA by 
nine EDTRS letters and reduced CRT by 90 μm. Incidence of adverse events was low, 
similar to ranibizumab. Currently moderate (grade B) to poor quality of evidence is 
available in support of bevacizumab for neo-vascular AMD. CONCLUSIONS: Based 
on current evidence (grade B) off-label Intravitreal bevacizumab seems to be safe and 
effective for the treatment of neo-vascular AMD in the short term, especially for 
underserved and ﬁnancially challenged communities.
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RETURN ON INVESTMENT OF ABLATIVE FRACTIONAL LASERS
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OBJECTIVES: Conduct a return on investment (ROI) analysis of 8 ablative fractional 
lasers used for cosmetic facial plastic surgery from the perspective of a facial plastic 
surgeon. METHODS: We identiﬁed 8 of the largest (based on sales volume) ablative 
fractional lasers for this analysis. ROI is (ΣTotal Revenue–ΣTotal Cost)/(ΣTotal Cost) 
and is deﬁned as the additional dollar returned from each dollar invested. Revenue 
was estimated as price per procedure multiplied by total number of procedures in a 
year. Total cost is a composite of purchase price and operating costs. In the base case 
analysis two purchase options were assumed 1) a 5 year lease with a $0 down payment 
and 2) a 3 year lease with a $0 down payment. In addition to monthly lease payments, 
included in the total cost estimate were service contracts, labor costs, and disposables. 
Sensitivity analyses were preformed to account for variability in cost and revenue 
assumptions. RESULTS: Revenue for each laser was estimated to be $51,072/year. 
Under a 5 year lease, the assumed total cost of each laser ranged from $115,827–
$240,597. This is compared to the total cost under a 3 year lease of each laser which 
ranged from $74,364–$124,878. Average ROI under the 5 year lease term was .54 
and ROI varied between −.03 (most expensive laser) and 1 (least expensive laser). The 
average 3 year ROI was .08, and ROI varied between -.35 (most expensive laser) and 
.38 (least expensive laser). CONCLUSIONS: Based on the assumptions of our analysis 
the laser with highest ROI was the least expensive laser. While ROI is an important 
ﬁnancial it should not be the sole means by which to determine a purchase. Physicians 
must also consider the clinical effectiveness of each laser and their own clinical judg-
ment when making such decisions.
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OBJECTIVES: Evaluate the annual cost of Dry Eye Diseases (DED) care in the United 
States from both a societal and a payer’s perspective METHODS: A decision-tree 
model was developed to estimate the annual cost for managing a cohort of DED 
patients with differing severity of symptoms and treatments utilizing data collected 
from survey and the literature. The direct costs included over the counter (OTC) 
medications, cyclosporine, punctal plugs, physician visits, and nutrition complements. 
The indirect costs were computed based on the self-reported productivity loss includ-
ing absenteeism and presenteeism. Multiple-one way sensitivity analysis was employed 
to evaluate the impact of changes in parameters within their 95% conﬁdence intervals 
on the cost estimate. RESULTS: In the base-case analysis, the total mean annual direct 
